LabCorp pays $85.3M to add LDL testing to its portfolio

LabCorp will pay $85.3 million to buy LipoScience, a company that uses nuclear magnetic resonance (NMR) to conduct cardiovascular diagnostic tests.

LipoScience markets a proprietary test that quantifies low-density lipoprotein (LDL) cholesterol. It uses NMR technology to identify lipoproteins and small molecules to diagnose cardiovascular and metabolic disorders.

The acquisition is expected to fortify LabCorp’s clinical decision support and testing programs. The companies plan to close the deal in the fourth quarter of 2014.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup